Kerui Peptide HongKongBPC-157
Ordered BPC-157 from Kerui Peptide HongKong? Mail in a sample (US only) and let us test it.
Test my supplyKerui Peptide HongKong BPC-157 evidence has turned negative: an Oct 1 identity failure followed by 99.29% purity below the 99.5% cutoff. Earlier May/Aug purity-fill passes make the pattern volatile, not clean.
A live Hong Kong company record is real, but WHOIS, hosting paths, and forum placement point away from a simple Hong Kong operating story. The report maps the Emily-KR/Iris1 sales trail, payment rails, and GLP-1 enforcement exposure.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Kerui Peptide HongKong rows.
Cancel anytime
About Kerui Peptide HongKong test results from Finnrick
Kerui Peptide HongKong is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 7 peptides and 42 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Kerui Peptide HongKong peptides in this dataset are BPC-157 (4 tests), GHK-Cu (4 tests) and NAD+ (4 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 42 recent tests.
Ordered BPC-157 from Kerui Peptide HongKong? Mail in a sample (US only) and let us test it.
Test my supply